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Abstract 18 
Dendritic cells (DC) are antigen-presenting cells that can be classified into three major cell 19 
subsets: conventional DC1 (cDC1), cDC2 and plasmacytoid DCs (pDC), none of which have 20 
been identified in horses. Therefore, the objective of this study was to identify and 21 
characterize DC subsets in equine peripheral blood, emphasizing on pDC. Surface marker 22 
analysis allowed distinction of putative DC subsets, according to their differential expression 23 
of CADM-1 and MHC class II. Equine pDC were found to be Flt3
+
 CD4
low
 CD13
-
 CD14
- 
24 
CD172a
-
 CADM-1
-
MHCII
low
. The weak expression of CD4 on equine pDC contrasts with 25 
findings in several other mammals. Furthermore, pDC purified by fluorescence-activated cell 26 
sorting were found to be the only cell subset able to produce large amounts of IFN-α upon 27 
TLR9-agonist stimulation. The pDC identity was confirmed by demonstrating high-levels of 28 
PLAC8, RUNX2 and TCF4 expression, showing pDC-restricted expression in other mammals.  29 
 30 
Keywords: horse, dendritic cell subset, plasmacytoid dendritic cell. 31 
 32 
Abbreviations: ODN, oligodeoxynucleotides; DC, dendritic cells; cDC, conventional DC; 33 
FMO, fluorescence minus one; Flt3, fms-like tyrosine kinase 3; Flt3L, Flt3 ligand; IFN,  34 
interferon; MoDC, monocyte-derived DC; pDC, plasmacytoid DC; PBMC, peripheral blood 35 
mononuclear cells.   36 
 
 
1. Introduction 37 
Dendritic cells (DC) represent the professional antigen-presenting cells of the immune system 38 
and are essential regulators of immunity and tolerance (Banchereau and Steinman, 1998). 39 
They can be further categorized into conventional DC (cDC), which are responsible for 40 
antigen presentation and induction of T-cell responses, and plasmacytoid DC (pDC) 41 
representing the most potent type I interferon (IFN) producing cell, able to efficiently sense 42 
microbial nucleic acid (Liu, 2005). Conventional DC consist of at least two phenotypically 43 
distinct subsets stimulating particular T-cell responses (Schlitzer and Ginhoux, 2014). The 44 
murine CD8α+/ human CD141+ cells comprise the cDC1 subset, specialized in cross-45 
presentation of antigens to CD8
+
 T-cells and stimulating Th1 immunity (Bachem et al., 2010; 46 
Jongbloed et al., 2010). The cDC2 subset was identified as murine CD11b
+
/ human CD1c
+
 47 
cells (Haniffa et al., 2013), and is particularly capable to stimulate Th2 and Th17 immunity 48 
(Dutertre et al., 2014; Tussiwand and Gautier, 2015). Both pDC and cDC arise from a 49 
common DC progenitor in the bone marrow (Liu and Nussenzweig, 2010; Onai et al., 2007) 50 
and are dependent on the growth factor fms-like tyrosine kinase 3 ligand (Flt3L) for their 51 
development and differentiation (Karsunky et al., 2003; Schmid et al., 2010). Accordingly, all 52 
DC subsets express Flt3 receptor (CD135). 53 
A number of reports described the presence of distinct cDC subpopulations in veterinary 54 
species, including pigs (Guzylack-Piriou et al., 2010; Maisonnasse et al., 2015; Summerfield 55 
et al., 2015; Auray et al., 2016, submitted), cattle (Howard et al., 1999; Renjifo et al., 1997) 56 
and sheep (Contreras et al., 2010; Pascale et al., 2008). Additionally, pDC have been 57 
identified in pig (Summerfield et al., 2003), in cattle (Reid et al., 2011) and in sheep (Pascale 58 
et al., 2008). 59 
However, neither cDC nor pDC have been described in horses. Studies that have been 60 
performed to date, resorted to the use of monocyte-derived dendritic cells (MoDC) (Cavatorta 61 
et al., 2009; Mauel et al., 2006; Moyo et al. 2013). Although MoDC possess many functional 62 
 
 
attributes consistent with DC (Sallusto and Lanzavecchia, 1994), they do not represent bona 63 
fide DC based on their ontogeny. Nevertheless, many in vivo studies report MoDC as a 64 
distinct subtype of inflammatory monocytic cell, sharing some features with cDC in terms of 65 
antigen presentation (Guilliams et al., 2014; Schlitzer et al., 2015). Consequently, for 66 
advances in immunological research in horses, it is essential to gain more information on 67 
equine bona fide DC. 68 
The aim of the present study was to phenotypically characterize equine blood DC and 69 
functionally identify pDC in healthy horses. As a first step, appropriate cell surface markers 70 
which were either equine-specific or shown to cross-react with the equine system were used 71 
to identify distinct cell subsets in equine peripheral blood mononuclear cells (PBMC) by flow 72 
cytometry. Based on the comparative approach used by Summerfield et al. (2015), a first 73 
classification of equine DC subsets is proposed. The identity of purified pDC was further 74 
confirmed by a robust IFN-α production upon TLR9-stimulation as well as by a high 75 
expression of pDC-specific transcripts. 76 
 77 
2. Methods 78 
2.1.Isolation of peripheral blood mononuclear cells from healthy horses 79 
Blood samples were collected from the jugular vein of eleven healthy horses (age = 4 – 21 80 
years) using sterile glass bottles supplemented with 5000 I.U./ml heparin (Liquemin
®
, 81 
Drossapharm AG, Basel, Switzerland) or Sodium-Heparin containing vacutainers (Vacuette
®
; 82 
Greiner, St.Gallen, Switzerland). The study was approved by the Animal Experimental 83 
Committee of the Canton of Berne and Vaud, Switzerland (No. BE 51/13). 84 
PBMC were isolated by density gradient centrifugation over Biocoll (ρ=1.077 g/ml, 85 
Biochrom GmbH, Berlin, Germany) as described (Hamza et al., 2007).  86 
 87 
2.2. Production of recombinant bovine Flt3 Ligand 88 
 
 
Bovine instead of equine Flt3L was used because the complete equine Flt3L gene sequence is 89 
still unknown. The partial equine Flt3L sequence (Genbank: XP_005596791.1) exhibits 73% 90 
amino acid sequence homology to bovine Flt3L. Bovine Flt3L (NCBI NM_181030.2) was 91 
produced as previously described (Guzylack-Piriou et al., 2010) and was originally employed 92 
for another study (Baumann et al., unpublished data). Briefly, after deletion of the stop codon, 93 
the Flt3L sequence was flanked by HindIII and XbaI restriction sites and was chemically 94 
synthesized in pUC57 plasmid (GenScript, Piscataway, NJ, USA). After HindIII and XbaI 95 
digestion, Flt3L was ligated in the pEAK8-His expression vector. The TOP10 Chemically 96 
Competent E. coli cells (Invitrogen, USA) were transformed with the plasmid pEAK8-His 97 
containing the bovine Flt3L. For final recombinant production of bovine Flt3L, HEK 293 98 
cells were transfected with pEAK8-His-Flt3L using X-tremeGENE 9 following the 99 
manufacturer’s instructions (Roche, Basel, Switzerland). After 5 days, supernatant was 100 
collected and expression of recombinant bovine Flt3L was assessed by western blot using an 101 
anti-his-HRP antibody (cat. no. 130-092-785, Miltenyi Biotec; Antibody Register: 102 
AB_1103231). The reaction was visualized with a WesternBright ECL Western blotting 103 
detection kit (Advansta Inc., Menlo Park, CA, USA) and a CCD-LAS3000 camera (Fuji Film) 104 
(Fig. S1). 105 
  106 
2.3. Surface marker analysis by flow cytometry 107 
PBMC from three horses were transferred to 5ml FACS tubes at 3 x 10
6
 cells per tube. First, a 108 
blocking step was performed using Chrome Pure whole mouse IgG (Jackson 109 
Immunoresearch, West Grove, PA, USA). All incubations were performed for 20 min on ice, 110 
followed by washing with PBS and centrifugation at 500 x g for 5 min. Briefly, cells were 111 
incubated with recombinant bovine Flt3L, followed by labelling with a PE-conjugated anti-his 112 
antibody (clone GG11-8F3.5.1,  cat-no 130-092-691; Miltenyi Biotec; Antibody Register: 113 
AB_1103227). Anti-human CADM-1 (cat no. CM004-3, MBL International Corporation; 114 
 
 
Antibody Registry: AB_592783), shown to specifically bind to the CADM-1 molecule in 115 
many mammalian species (Contreras et al., 2010; Dutertre et al., 2014), was detected by a 116 
secondary goat biotinylated anti-chicken antibody (cat no 103-065-155, Jackson 117 
Immunoresearch; Antibody Registry: AB_2337383), followed by labelling using Brilliant 118 
Violet (BV)421 conjugated to Streptavidin (BD Biosciences, Franklin Lakes, NJ, USA). 119 
Other surface markers were stained using the following antibodies: anti-equine CD4 (clone 120 
CVS4; cat no  MCA1078, Bio-Rad; Antibody Register AB_321274), anti-equine CD13 (clone 121 
CVS19; cat no  MCA1084GA, Bio-Rad; Antibody Registry: AB_321308), anti-equine 122 
MHCII (clone CVS20; cat no  MCA1085, BioRad; Antibody Register AB_321618), anti-123 
equine CD14 (clone 105; https://courses2.cit.cornell.edu/wagnerlab/research/reagents.htm; 124 
Kabithe et al., 2010)), anti-bovine CD172a (clone HR-DH59B; cat no HR-BOV2049; 125 
Monoclonal Antibody center, Washington State University; Pullman WA, USA ) showing 126 
cross-reactivity with equine cells (Mérant et al., 2009). These monoclonal antibodies were 127 
labelled with mouse IgG1 Alexa Fluor 488, 647 or 700 Zenon labelling kits (Thermo 128 
Scientific, Waltham MA, USA). Appropriate isotype and fluorescence-minus-one (FMO) 129 
controls were used. Finally, cells were resuspended in phosphate buffered saline (PBS) and 130 
analysed on a LSRII flow cytometer (BD Biosciences).  Automated compensation for spectral 131 
overlap of fluorochromes was calculated by the BD FACSDIVA acquisition software (BD 132 
Biosciences) based on single-stained PBMC. Data were analysed using FlowJo software 6 133 
(Tree Star Inc. Ashland OR, USA). Gates were set to exclude doublets and lymphocytes 134 
based on forward and side scatter characteristics (Fig. 1A). Within this cell population, a 135 
further gate was set on Flt3
+
/ CD14
low
 cells, based on isotype and fluorescence minus one 136 
(FMO) controls. This gating strategy was used for all flow cytometry experiments. 137 
 138 
2.4. PBMC stimulation for IFN-α production 139 
 
 
PBMC were isolated as described above and suspended in RPMI 1640 medium with HEPES 140 
and L-glutamine (Gibco, Life Technologies Ltd, Paisley UK) supplemented with 1% 141 
penicillin and streptomycin (Gibco), 1% MEM vitamins, 1% Na pyruvate, 1% Non-essential 142 
amino acids (all Biochrom GmbH) and 10% inactivated horse serum (Ziegler et al. 2016, in 143 
revision) at a density of 2 x 10
5
 cells per 200 µl medium in a 96-well round-bottom cell 144 
culture plate (Sarstedt, Nümbrecht, Germany). Cells were cultured for 24h in the presence of 145 
5 μg/ml of the synthetic TLR9 agonist Type C CpG-oligodeoxynucleotides (ODN) D-SL03 146 
(InvivoGen, San Diego, CA, USA) or of equine herpesvirus-1 (EHV-1; MOI of 0.04 TCID50/ 147 
cell, EHV1-V144/64, kindly supplied by Prof. Reto Zanoni from the Institute for Virology 148 
and Immunology, Vetsuisse Faculty, University of Berne, Switzerland). Thereafter, cell 149 
culture supernatants were collected and stored at -80°C until used. 150 
 151 
2.5. Enrichment of pDC by depletion of PBMC from CD5
+
 and CD14
+ 
cells 152 
PBMC were depleted of CD5
+ 
and CD14
+ 
cells by magnetic separation (MACS technology, 153 
Miltenyi Biotec GmbH) according to standard protocols by the manufacturer, using a 154 
monoclonal anti-equine CD5 antibody (clone CVS5; cat no MCA1079GA, Bio-Rad;  155 
Antibody Register: AB_321382) and anti-equine CD14 (clone 105, Kabithe et al., 2010). 156 
Briefly, PBMC were first incubated with anti-CD5 and anti-CD14 simultaneously and, after a 157 
washing step, with secondary goat anti-mouse micro beads. Cells were then separated on a 158 
LD column (Miltenyi Biotec GmbH). After washing, the CD5/ CD14-depleted (purity > 75%) 159 
and CD5/ CD14-enriched (purity > 95%) fraction were stimulated with CpG-ODN or EHV-1 160 
as described above for 24h and supernatants were harvested and stored at -80°C until used. 161 
 162 
2.6. Sorting experiments 163 
Flt3
+ 
cells from three horses were enriched from PBMC by MACS separation as described 164 
above, using the recombinant bovine Flt3L bound by an anti-his antibody conjugated to PE 165 
 
 
and ultra-pure anti-PE microbeads (both Miltenyi Biotec GmbH). The magnetic separation 166 
was performed at 4°C. Following Flt3-enrichment, cells were stained for expression of CD14, 167 
CADM-1 and MHCII as mentioned above. Using a BD FACSAria sorter, Flt3
+
CD14
low 
cells 168 
were gated. MHCII
low
/ CADM-1
-
, MHCII
high
/ CADM-1
low
 and MHCII
high
/ CADM-1
+
 169 
subpopulations were identified and sorted. Sorted cells were used for subsequent stimulation 170 
with the TLR9 agonist CpG-ODN D-SL03, as described above, using 20’000 cells/ 100 µl 171 
medium per well. The remaining cells were resuspended in 1ml Isol-RNA Lysis Reagent (5 172 
Prime, Hilden, Germany) and kept at -80°C until used. 173 
 174 
2.7. Equine IFN-α ELISA  175 
For detection of IFN-α in cell culture supernatants, we used an equine IFN-α ELISA (kindly 176 
supplied by Dr. Bettina Wagner, Cornell University, Ithaca NY, USA). The assay was 177 
performed as described (Wagner et al., 2008). Briefly, anti-IFN-α (clone 29B; 178 
https://courses2.cit.cornell.edu/wagnerlab/research/reagents.htm) was used for coating of the 179 
plates at a concentration of 5 µg/ml. rIFN-a/IgG4 supernatant (85 ng/ml) was serially diluted 180 
two-fold, ranging from 42.5 ng/ml – 0.66 ng/ml, to obtain a standard curve. Cell culture 181 
supernatants of stimulated cells were tested in duplicates at a 1:2 dilution. For detection, 182 
biotinylated anti-IFN-α (clone 240; 183 
https://courses2.cit.cornell.edu/wagnerlab/research/reagents.htm) was used. This step was 184 
followed by incubation with streptavidin-peroxidase and TMB substrate (Sigma-Aldrich 185 
GmbH, Buchs, Switzerland). Optical density was measured at 450 nm on an ELISA Reader 186 
(BioTek Instruments Inc., Winooski VT, USA) and IFN-α concentration in the samples was 187 
calculated according to the standard curve calculated by the Gen5 software (BioTek 188 
Instruments Inc.). 189 
 190 
2.8. Quantitative Reverse-Transcriptase Polymerase Chain Reaction (qRT-PCR) 191 
 
 
For RNA extraction from sorted PBMC fractions, 200 µl of chloroform:IAA (49:1; Sigma-192 
Aldrich GmbH) were added to 1 ml of Isol-RNA lysate and tubes were vigorously shaken by 193 
hand. After 5 min incubation at room temperature, samples were centrifuged at 12,000 x g for 194 
15 min. The aqueous upper phase was subsequently transferred to a fresh tube and 500 µl of 195 
100% isopropanol were added. Precipitated RNA was then loaded onto a spin column from 196 
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) and purification was performed 197 
according to manufacturer’s instructions. RNA was eluted in 40 µl of RNAse-free H2O. Each 198 
sample was quantified spectrophotometrically (NanoDrop 1000, Thermo Scientific) and 199 
stored at -80 °C until used.  A total of 9 µl of RNA was employed to synthesize cDNA using 200 
GoScript™ Reverse Transcription system (Promega, Madison WI, USA) following 201 
manufacturer’s instructions. Expression of PLAC8, RUNX2, TCF4 and BACT were quantified 202 
by qPCR using the GoTaq® qPCR Master Mix (Promega) with the primers listed in the table 203 
S1. The reaction was performed in a total volume of 25 μl in the 7500 real-time PCR system 204 
(Applied Biosystems, Foster City, CA, USA) under the following fast-cycle amplification 205 
conditions: 2 min at 95°C, followed by 40 cycles of denaturation at 95°C for 3 seconds 206 
followed by annealing/ extension at 58°C for 30 seconds. The specificity of each primer pair 207 
was confirmed in melting-curve analysis and primer efficiency reached > 90% by using serial 208 
cDNA dilution as template. Relative expression was normalized to the housekeeping gene 209 
BACT expression and ΔCt was calculated as: 2-Ct gene / 2-Ct housekeeping gene. 210 
 211 
2.9 Statistical Analysis 212 
Statistical analysis was carried out using the software program NCSS8. As the data were not 213 
normally distributed, a non-parametric Wilcoxon (signed rank) test was used to compare 214 
levels of secreted IFN-α between stimulation conditions. P-values ≤ 0.05 were considered 215 
significant. 216 
 217 
 
 
3. Results and Discussion 218 
3.1. Surface marker expression of equine dendritic cell subsets 219 
Since the Flt3 expression on DC is well conserved in mammals (Karsunky et al., 2003; 220 
Schmid et al., 2010; Summerfield et al., 2015), Flt3L constitutes a valuable tool to identify 221 
DC in a mixed cell population. Orthologous bovine Flt3L was shown to bind to a small 222 
heterogeneous population of equine PBMC (0.42 – 0.85%) which did not express CD14 at all, 223 
or at very low levels only (Fig 1B).  224 
Within the Flt3
+
/ CD14
low 
gate, three subpopulations (P4, P5 and P6) could be further 225 
identified based on the differential expression of MHCII and CADM-1 (Fig. 1C). P4 was 226 
found to express the lowest levels of CD172a, while P5 expressed high levels, comparable to 227 
monocytes (Fig. 1D).  None of the subsets was found to express high levels of CD4 (Fig. 1D).  228 
Interestingly, CD13 was co-expressed with CADM-1 on a population within Flt3
+
CD14
low
 229 
cells (Fig. 1D). In alignment with other species and considering that CADM-1, CD13, Flt3 230 
and CD172a represent cell surface receptors with a species-conserved expression 231 
(Summerfield et al., 2015), we propose that equine cDC1 can be identified as Flt3
+
CD4
-232 
CD13
+
CD14
low
CD172a
-
CADM-1
+
MHCII
 high
 cells, while equine  cDC2 would be Flt3
+
CD4
-233 
CD13
-
CD14
low
CD172a
+
CADM-1
low
MHCII
 high
. This will require future confirmation for 234 
example by employing transcriptional profiling of the sorted populations. As the present study 235 
was focusing on pDC we continued our experimentation focusing on the Flt3
+
CD4
-
 CD13
-236 
CD14
-
CD172a
-
CADM-1
-
MHCII
low
 subset as a possible candidate for pDC.  237 
 238 
3.2. Functional identification of equine pDC 239 
As a first experiment, PBMC from eleven healthy horses were stimulated with the synthetic 240 
TLR9 agonist type C CpG-ODN or with EHV-1 and the amount of IFN-α in the supernatants 241 
was quantified by ELISA. A significant IFN-α induction could be observed in cells stimulated 242 
with both EHV-1 and CpG-ODN compared to unstimulated cells (Fig.2A). Intriguingly, while 243 
 
 
an induction of IFN-α by EHV-1 was shown in PBMC from all horses, five out of the eleven 244 
tested horses were non-responsive to stimulation by CpG-ODN (Fig. 2A). The strongest 245 
induction of IFN-α in response to CpG-ODN was detectable with PBMC of horses, which 246 
also released the highest quantities of IFN-α in response to EHV-1. We speculate that there 247 
was a higher number of pDC present in the PBMC of these horses. On the other hand, EHV-1 248 
contains a number of pathogen-associated molecular patterns. It may have been able to induce 249 
IFN-α production through a broader stimulation of various pathways, possibly also in other 250 
cells than pDC, thus inducing IFN-α secretion also in PBMC of horses which were 251 
unresponsive to CpG-ODN stimulation. In order to enrich the pDC population, PBMC were 252 
depleted of CD5
+ 
T-cells and CD14
+ 
monocytes. Whereas CD5-/CD14-depleted PBMC 253 
released high levels of IFN-α, no response was observed in CD5-/CD14-enriched fractions 254 
after CpG or virus stimulation (Fig. S2). These data indicate that the pDC do not express CD5 255 
and CD14. 256 
To further confirm pDC identity and to obtain sufficient cell numbers for FACS sorting, Flt3
+
 257 
cells were enriched by MACS sorting, resulting in 7% Flt3
+
 cells (range 3 – 10.1%), which 258 
represented an 11-fold enrichment (data not shown). Similar to what we observed with 259 
PBMC, three cell subsets could be clearly distinguished in the CD14
low
/ Flt3
+
 fraction with 260 
regard to MHCII and CADM-1 expression (Fig. 2B). They were subsequently sorted by 261 
FACS. Stimulation of PBMC, Flt3 MACS-enriched and Flt3 MACS-depleted fractions with 262 
CpG-ODN revealed distinct differences in IFN-α induction, confirming the presence of pDC 263 
in the Flt3
+
 cells (Fig. 2C). Slight increase in IFN-α secretion was observed in the Flt3 264 
MACS-enriched compared to PBMC (median; range = 14.1; 9.1 – 22.2 ng/ml and 9.7; 0.23 – 265 
11.9 ng/ml, respectively), whereas no IFN-α production could be detected in the Flt3-depleted 266 
fraction. As hypothesized, IFN-α was solely produced by the P4 fraction of putative pDC 267 
(median 20.2; range 15.9 – 50.3 ng/ml), with no IFN-α production detected in the other two 268 
subsets, indicating that the P4 subset would represent pDC. 269 
 
 
Recent breakthroughs in transcriptomic profiling of DC subsets have revealed cell-type 270 
specific transcripts some of which were conserved between species (Miller et al., 2012; Shay 271 
et al. 2013).  Thus, new possibilities have opened up for characterization of DC subsets in 272 
veterinary species (Summerfield et al., 2015; Vu Manh et al., 2015). Moreover, expression 273 
analysis of genes known to be specifically expressed in pDCs in other species including 274 
PLAC8 (=C-15) (Rissoan et al., 2002), RUNX2 (Sawai et al., 2013) and TCF4 (= E2-2) (Cisse 275 
et al., 2008) revealed a high expression in the putative equine pDC fraction (Fig. 2D). While 276 
RUNX2 levels were found to be low in the P5 cell fraction, no expression of the other 277 
transcripts was detected, indicating that PLAC8 and TCF4 represent pDC-specific transcripts 278 
also in horses. We found a similar restricted expression of these genes in porcine pDC (Auray 279 
and Summerfield, unpublished results). While the function of PLAC8 on pDC is unknown, 280 
RUNX2 and in particular TCF4 represent essential transcription factors for their development 281 
(Sawai et al., 2013; Cisse et al., 2008). Considering the transcriptions factors controlling 282 
immune cell development are well conserved, this data confirms that the Flt3
+
CD4
-
 CD13
-
283 
CD14
-
CD172a
-
CADM-1
-
MHCII
low
 P4 subset represents or contains equine pDC.  284 
In summary, we have identified equine pDC and propose a basis for further characterization 285 
of equine blood cDC. Alignment of the phenotype of equine pDC with other species 286 
highlighted some intriguing differences, such as a very low or lacking expression of CD4, 287 
contrasting with several other mammals (Summerfield et al., 2015). Considering the 288 
importance of DC in many immunological processes, future work should follow to identify 289 
DC-subset specific transcripts, which will be the basis to establish reagents for equine DC 290 
characterization.  291 
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Figure Legends 426 
Figure 1. 427 
Phenotype of Flt3
+
 cells in equine PBMC. (A) Gating strategy to remove doublets and include 428 
FSC
high
/ SSC
high
 large cells. A total number of 250’000 cells were acquired. (B) Within the 429 
single, large cell gate, based on the fluorescence minus one (FMO) control, a gate on 430 
Flt3
+
CD14
- 
cells was set. (C) Identification of three putative DC subpopulations based on 431 
MHCII and CADM-1 expression within Flt3
+
CD14
-
 gated cells. (D) Histograms showing the 432 
expression levels of CD172a, CD4 and CD13 in P4 (red; pDC), P5 (blue; cDC2) and P6 433 
(orange; cDC1) compared to PBMC (grey). Data are shown for one representative animal out 434 
of three. 435 
 436 
Figure 2.  437 
Characterization of equine pDC. (A)
 
 IFN-α secretion by equine PBMC upon stimulation with 438 
CpG-ODN (5 µg/ml) or EHV-1 (MOI of 0.04 TCID50/cell). Samples were tested in duplicates 439 
and results are displayed as mean optical density (OD) measured at 450 nm. Each symbol 440 
indicates a separate horse with red lines indicating the median. A non-parametric paired 441 
sample Wilcoxon signed rank test was performed to compare the stimulation conditions. P-442 
values ≤ 0.05 were considered statistically significant as indicated by asterisks. (B) Gating 443 
strategy of putative DC subsets within Flt3-enriched cells which were employed for FACS. A 444 
gate was set on the Flt3
+
/ CD14
low
 cells. The three distinct cell populations in the CADM-1/ 445 
MHCII plot were then gated and sorted. (C) IFN-α was detected in cell culture supernatants of 446 
PBMC (white background), Flt3-enriched and Flt3-depleted fractions, respectively (light 447 
green background) as well as FACS-sorted DC subsets (red background) stimulated with 5 448 
μg/ml CpG-ODN for 24h. Each symbol represents an individual horse with red lines 449 
indicating the median. Samples were tested in duplicates and results are displayed as ng/ml. 450 
(D) Relative expression of PLAC8, RUNX2 and TCF4 transcripts in the sorted populations P4, 451 
 
 
P5 and P6. The expression was normalized to the housekeeping gene BACT. Bars show the 452 
mean +/- SD of an independent experiment performed in duplicate. One representative sorting 453 
out of three is shown. 454 
 455 
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Table S1. Primers used for qRT-PCR. 461 
Transcription Factor Gene Primer  Sequence 
PLAC8 Forward 
Reverse 
5’ GCCAGTGGTCATTGTGACTC 
5’ GATCCAGGGATGCCATATCG 
RUNX2 Forward 
Reverse 
5’ GGCAAGAGTTTCACCTTGAC 
5’ GAATGCGCCCTAAATCACTG 
TCF4 Forward 
Reverse 
5’ CCACCTCAAGAGTGACAAAC 
5’ TTTCAGACACGCAGCTTTCG 
BACT Forward 
Reverse 
5’ CACCACACCTTCTACAAC 
5’ ATCTGGGTCATCTTCTCG 
 462 
Table S2. Proposed classification of equine dendritic cell subsets in the blood based on 463 
surface marker expression. 464 
DC subset Flt3 CD4 CD14 CD172a CD13 CADM-1 MHCII 
cDC1 + - (-) - + + ++ 
cDC2 + - (-) + - - ++ 
pDC + (-) - - - - + 
 465 
 466 
 467 
 468 
 469 
Figure S1. Recombinant bovine Flt3L expressed in HEK293 cells was visualized by Western 470 
blotting. A total of 20 µl of 10-fold diluted supernatant was loaded on the gel. The Flt3L was 471 
detected with an mouse anti-His-HRP antibody (Miltenyi Biotec, Antibody Register: 472 
Antibody Register: AB_1103231) and visualized with a WesternBright ECL Western blotting 473 
detection kit (Advansta Inc., Menlo Park, CA, USA)   474 
 475 
 476 
